Recursion Pharmaceuticals, Inc. (RXRX) Net Income by Year
Recursion Pharmaceuticals, Inc. reported a net loss of $644.8M in fiscal year 2025. This represents a decrease of 39.1% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $518.9M net loss. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Recursion Pharmaceuticals, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
RXRX Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
RXRX Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Recursion Pharmaceuticals, Inc. financials
Frequently Asked Questions
What was Recursion Pharmaceuticals, Inc.'s net income in fiscal year 2025?
Recursion Pharmaceuticals, Inc. reported a net loss of $644.8M in fiscal year 2025.
How fast is Recursion Pharmaceuticals, Inc.'s net income growing?
Recursion Pharmaceuticals, Inc. (RXRX) net income fell by 39.1% year over year, from -$463.7M to -$644.8M in fiscal year 2025.
What is Recursion Pharmaceuticals, Inc.'s net income over the last twelve months?
Recursion Pharmaceuticals, Inc. (RXRX) reported a $518.9M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Recursion Pharmaceuticals, Inc.'s net income changed over the years?
Across the 7 fiscal years this page covers, Recursion Pharmaceuticals, Inc. (RXRX) net income went from -$61.9M in fiscal year 2019 to -$644.8M in fiscal year 2025.
What was Recursion Pharmaceuticals, Inc.'s net income in the most recent quarter?
Recursion Pharmaceuticals, Inc. (RXRX) reported -$131.0M in net income in Q2 2026. This represents an increase of 23.8% from the same quarter a year earlier.
What does net income mean on a financial statement?
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Recursion Pharmaceuticals, Inc. (RXRX) reported on that line in every period on record.